Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate

NCT ID: NCT01857531

Last Updated: 2014-09-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2014-02-28

Brief Summary

The purpose of this research study is to evaluate whether the investigational drug ganaxolone can help smokers quit smoking. Ganaxolone is a drug that has been investigated (in other research studies) for the treatment of seizures and migraines. This drug is considered investigational in the US.

Detailed Description

The purpose of this proof-of-concept study is to evaluate whether expired air carbon monoxide (CO) will be reduced and smoking cessation success rates enhanced for smokers who receive the neurosteroid analog ganaxolone. The trial will be seeking preliminary indications of efficacy and tolerability in the smoking population and allow us to estimate effect sizes for future controlled trials.

Conditions

Smoking Cessation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ganaxolone -- Nicotine Patch

Pre-Quit Period:

Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.

Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.

Post-Quit Period:

Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.

Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk.

Group Type: EXPERIMENTAL

Ganaxolone

Intervention Type: DRUG

Pre-Quit Period:

Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.

Post-Quit Period:

Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three.

Nicotine Patch

Intervention Type: DRUG

Pre-Quit Period:

Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.

Post-Quit Period:

Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week).

Interventions

Ganaxolone

Pre-Quit Period:

Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.

Post-Quit Period:

Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three.

Intervention Type: DRUG

Nicotine Patch

Pre-Quit Period:

Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.

Post-Quit Period:

Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week).

Intervention Type: DRUG

Other Intervention Names

nicoderm

Eligibility Criteria

Inclusion Criteria

• Have no known serious medical conditions;
• Are 18-65 years old;
• Smoke an average of at least 10 cigarettes per day;
• Have smoked at least one cumulative year;
• Have an expired air CO reading of at least 10ppm;
• Able to read and understand English;
• Express a desire to quit smoking in the next thirty days.

Potential subjects must agree to use acceptable contraception during their participation in this study.

Potential subjects must agree to avoid the following during their participation in this study:

• participation in any other nicotine-related modification strategy outside of this protocol;
• use of tobacco products other than cigarettes, including pipe tobacco, cigars, e-cigarettes, snuff, and chewing tobacco;
• use of experimental (investigational) drugs or devices;
• use of illegal drugs;
• use of opiate medications;
• consumption of grapefruit or grapefruit juice for the first six weeks of study participation;
• use of melatonin;
• use of sedating antihistamines for the first six weeks of study participation;
• use of alcohol during the first six weeks of study participation.
• use of benzodiazepines

Exclusion Criteria

• Inability to attend all required experimental sessions;
• Inability to take oral drugs or adhere to medication regimens;
• Hypertension (systolic >140 mm Hg, diastolic >90 mm Hg);
• Hypotension with symptoms (systolic <90 mm Hg, diastolic <60 mm Hg).
• Coronary heart disease;
• Lifetime history of heart attack;
• Clinically significant cardiac rhythm disorder (irregular heart rhythm);
• Chest pains;
• Cardiac (heart) disorder;
• Extensive active skin disorder;
• Liver or kidney disorder;
• Gastrointestinal disease other than gastroesophageal reflux or heartburn;
• Active ulcers in the past 30 days;
• Currently symptomatic lung disorder/disease;
• Brain abnormality;
• Migraine headaches that occur more frequently than once per week;
• History of seizures;
• Recent, unexplained fainting spells;
• Problems giving blood samples;
• Diabetes (unless treated with diet and exercise alone);
• Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);
• Other major medical condition;
• Current symptomatic psychiatric disease;
• Current depression;
• Current suicidal ideation or history of suicide attempt (in the past 5 years);
• Pregnant or nursing mothers;
• Use (within the past 30 days) of:

• Illegal drugs (or if the urine drug screen is positive),
• Experimental (investigational) drugs;
• Psychiatric medications including antidepressants, antipsychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);
• Corticosteroids;
• Cytochrome P450 341 (CYP3A4) inhibitors and inducers;
• Smokeless tobacco (chewing tobacco, snuff), pipes or e-cigarettes;
• Wellbutrin, bupropion, Zyban, Chantix, varenicline, nicotine replacement therapy or any other smoking cessation aid.
• Use (within the past 14 days) of:

• dehydroepiandrosterone (DHEA), Pregnenolone or ganaxolone;
• Opiate medications for pain or sleep;
• Benzodiazepines or other drugs with significant sedating or anticholinergic activity;
• Use of more than one cigar a month;
• Regular alcohol use;
• Significant adverse reaction to nicotine patches in the past.
• Significant past adverse reaction to ganaxolone in the past.
• Current participation or recent participation (in the past 30 days) in another smoking study at our center or another research facility.
• Current participation in another research study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: collaborator

Jed E. Rose

OTHER

Sponsor Role: lead

Responsible Party

Jed E. Rose

Professor, Department of Psychiatry and Behavioral Sciences

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jed E Rose, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Duke Center for Smoking Cessation

Charlotte, North Carolina, United States

Duke Center for Smoking Cessation

Durham, North Carolina, United States

Duke Center for Smoking Cessation

Raleigh, North Carolina, United States

Duke Center for Smoking Cessation

Winston-Salem, North Carolina, United States

Countries

United States

Other Identifiers

1P50DA027840-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Pro00041533

Identifier Type: -

Identifier Source: org_study_id